The Social Security (Industrial Injuries) (Prescribed Diseases) Amendment Regulations 2017

Type Statutory-Instrument
Publication 2017-03-01
State In force
Department King's Printer of Acts of Parliament
PDF Download
articles Not indexed
Reform history JSON API

Made: 1st March 2017

Laid before Parliament: 6th March 2017

Coming into force: 30th March 2017

The Secretary of State is satisfied of the matters referred to in section 108(2) of that Act.

Citation, commencement and interpretation

1

Amendment of regulation 4 of the Principal Regulations

2

In regulation 4 of the Principal Regulations (presumption that a disease is due to the nature of employment)[^f00004], in paragraph (2) after “C32,” insert “C34,”.

Amendment of Schedule 1 to the Principal Regulations

3

A1 Leukaemia (other than chronic lymphocytic leukaemia) or primary cancer of the bone, bladder, breast, colon, liver, lung, ovary, stomach, testis or thyroid.

C34 Extrinsic allergic alveolitis.

Exposure to ionising radiation where the dose is sufficient to double the risk of the occurrence of the condition.

Exposure to airborne isocyanates; or to any other chemical substance that causes extrinsic allergic alveolitis.

Signed

Signed by authority of the Secretary of State for Work and Pensions

Penny Mordaunt — Minister of State — Department for Work and Pensions — 1st March 2017

Explanatory note

(This note is not part of the Regulations)

EXPLANATORY NOTE

These Regulations make amendments to the Social Security (Industrial Injuries) (Prescribed Diseases) Regulations 1985 (S.I. 1985/967) (“the Principal Regulations”).

Regulation 2 amends regulation 4(2) of the Principal Regulations to include new prescribed disease C34 (extrinsic allergic alveolitis).

Regulation 3 makes amendments to Schedule 1 to the Principal Regulations. It amends the prescriptions for prescribed diseases A1 (leukaemia (other than chronic lymphocytic leukaemia) or primary cancer of the bone, bladder, breast, colon, liver, lung, ovary, stomach, testis or thyroid), B6 (extrinsic allergic alveolitis) and D9 (unilateral or bilateral diffuse pleural thickening). It also inserts new prescribed disease C34.

A full impact assessment has not been published for this instrument as it has no impact on the private sector or civil society organisations.

Footnotes

[^f00001]: See sections 171 and 172(2) of the Social Security Administration Act 1992 (c. 5).

[^f00002]: 1992 c. 4. Section 175(1) and (4) is amended by the Social Security Contributions (Transfer of Functions, etc.) Act 1999 (c. 2) and section 175(5) is amended by the Social Security (Incapacity for Work) Act 1994 (c. 18). See section 122(1) of the Social Security Contributions and Benefits Act 1992 (c. 4) for the meaning of “prescribe”.

[^f00003]: S.I. 1985/967.

[^f00004]: Substituted by S.I. 2015/87.

[^f00005]: Amended by S.I. 1986/1374, 1987/335 and 2112, 1989/1207, 1991/1938, 1993/862 and 1985, 1994/2343, 1996/425, 1997/810, 2000/1588, 2003/270 and 2190, 2005/324, 2006/586, 2007/811 and 1753, 2008/14 and 1552, 2009/1396, 2011/1497, 2012/647 and 1634 and 2015/87.

Reading this document does not replace reading the official text published on legislation.gov.uk. Contains public sector information licensed under the Open Government Licence v3.0. We assume no responsibility for any inaccuracies arising from the conversion of the original CLML XML to this format.

This text is published under legislation.gov.uk's own terms of reuse, not a Legalize or public-domain licence. legislation.gov.uk
Open Government Licence v3.0 (attribution required)
© Crown and database right. Derived from content available under the Open Government Licence v3.0 from legislation.gov.uk.